Hospital or health organisation · founded 1941

Providence Portland Medical Center

Portland, United States · oregon.providence.org/location-directory/p/providence-portland-medical-center

Part of Providence Health & Services Oregon and Southwest Washington

Manage this page

Citations, last 5 years: 11.5k
Works, last 5 years: 734
h-index: 257
Scientists listed: 57
Grants since 2016: 28

Grants received

2025 · training · HIP Resident Award

HIP Resident Award 2025: Nidhi Patel

Nidhi Patel · Providence Portland Medical Center · funded by American Society of Hematology

2022–2025 · career development · K22

Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer

Terry R Medler · Providence Portland Medical Center · funded by National Institutes of Health

$162kInflammasome and immune disorders

2022–2025 · career development · K22

Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer

Terry R Medler · Providence Portland Medical Center · funded by National Institutes of Health

$162kInflammasome and immune disorders

2022–2025 · career development · K22

Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer

Terry R Medler · Providence Portland Medical Center · funded by National Institutes of Health

$162kInflammasome and immune disorders

2021–2027 · research · R01

Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response

Brendan D Curti · Providence Portland Medical Center · funded by National Institutes of Health

$571.1kGalectins and Cancer Biology

2021–2027 · research · R01

Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response

Brendan D Curti · Providence Portland Medical Center · funded by National Institutes of Health

$582.9kGalectins and Cancer Biology

2021–2024 · research · R21

Elucidating the role of intratumoral microbiota on immunotherapy efficacy

William L Redmond · Providence Portland Medical Center · funded by National Institutes of Health

$191.3k

2021–2023 · research · R21

Elucidating the role of intratumoral microbiota on immunotherapy efficacy

William L Redmond · Providence Portland Medical Center · funded by National Institutes of Health

$234.2k

2021–2027 · research · R01

Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response

Brendan D Curti · Providence Portland Medical Center · funded by National Institutes of Health

$593.1kGalectins and Cancer Biology

2021–2027 · research · R01

Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response

Brendan D Curti · Providence Portland Medical Center · funded by National Institutes of Health

$1.2M

2019–2024 · research · R01

Rewiring the myeloid cell response to adjuvants to improve tumor control

Michael James Gough · Providence Portland Medical Center · funded by National Institutes of Health

$377.4kImmune cells in cancer

2019–2024 · research · R01

Rewiring the myeloid cell response to adjuvants to improve tumor control

Michael James Gough · Providence Portland Medical Center · funded by National Institutes of Health

$369.9kImmune cells in cancer

2019–2024 · research · R01

Rewiring the myeloid cell response to adjuvants to improve tumor control

Michael James Gough · Providence Portland Medical Center · funded by National Institutes of Health

$358.6kImmune cells in cancer

2019–2024 · research · R01

Rewiring the myeloid cell response to adjuvants to improve tumor control

Michael James Gough · Providence Portland Medical Center · funded by National Institutes of Health

$377.4kImmune cells in cancer

2019–2024 · research · R01

Rewiring the myeloid cell response to adjuvants to improve tumor control

Michael James Gough · Providence Portland Medical Center · funded by National Institutes of Health

$369.9kImmune cells in cancer

2017–2018 · research · LJAF

Providence Portland Medical Center

Providence Portland Medical Center · funded by Arnold Ventures

$40.2kOpioid Use Disorder Treatment

2016–2018 · research · R21

Increasing the potency of Listeria monocytogenes-based vaccines by eliminating vaccine-related gamma delta T cell responses.

Marka Crittenden · Providence Portland Medical Center · funded by National Institutes of Health

$247.5kListeria monocytogenes in Food Safety

2016–2021 · research · R01

(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.

Marka Crittenden · Providence Portland Medical Center · funded by National Institutes of Health

$377.4kinterferon and immune responses

2016–2021 · research · R01

(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.

Marka Crittenden · Providence Portland Medical Center · funded by National Institutes of Health

$377.4kinterferon and immune responses

2016–2021 · research · R01

(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.

Marka Crittenden · Providence Portland Medical Center · funded by National Institutes of Health

$377.4kinterferon and immune responses

2016–2021 · research · R01

(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.

Marka Crittenden · Providence Portland Medical Center · funded by National Institutes of Health

$377.4kinterferon and immune responses

2016–2019 · research · R21

Increasing the potency of Listeria monocytogenes-based vaccines by eliminating vaccine-related gamma delta T cell responses.

Marka Crittenden · Providence Portland Medical Center · funded by National Institutes of Health

$206.3kListeria monocytogenes in Food Safety

2016–2021 · research · R01

(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.

Marka Crittenden · Providence Portland Medical Center · funded by National Institutes of Health

$366.1kinterferon and immune responses

2014–2024 · research · R01

High dose radiation therapy to direct immune responses to pancreatic cancer

Michael James Gough · Providence Portland Medical Center · funded by National Institutes of Health

$391.9kCancer Immunotherapy and Biomarkers

2014–2024 · research · R01

High dose radiation therapy to direct immune responses to pancreatic cancer

Michael James Gough · Providence Portland Medical Center · funded by National Institutes of Health

$391.9kCancer Immunotherapy and Biomarkers

2014–2024 · research · R01

High dose radiation therapy to direct immune responses to pancreatic cancer

Michael James Gough · Providence Portland Medical Center · funded by National Institutes of Health

$391.9kCancer Immunotherapy and Biomarkers

2014–2024 · research · R01

High dose radiation therapy to direct immune responses to pancreatic cancer

Michael James Gough · Providence Portland Medical Center · funded by National Institutes of Health

$384kCancer Immunotherapy and Biomarkers

2014–2024 · research · R01

High dose radiation therapy to direct immune responses to pancreatic cancer

Michael James Gough · Providence Portland Medical Center · funded by National Institutes of Health

$384kCancer Immunotherapy and Biomarkers